The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Implementation and preliminary validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in patients receiving radionuclide therapy for prostate cancer.
 
Lisa Gudenkauf
No Relationships to Disclose
 
Tugce Telli
No Relationships to Disclose
 
Astrid Delker
No Relationships to Disclose
 
Danielle Simon
No Relationships to Disclose
 
Heather Jim
Consulting or Advisory Role - SBR Bioscience
Research Funding - Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Methods of Treating Cognitive Impairment, United States Letters Patent No. 10806772, 10/20/2020
 
Laura Oswald
No Relationships to Disclose
 
Xiaoyin Li
No Relationships to Disclose
 
Aasha Hoogland
No Relationships to Disclose
 
Adam Dicker
Stock and Other Ownership Interests - Oncohost
Consulting or Advisory Role - Aptar Pharma; Caris Life Sciences; CVS; Guardant Health; Janssen; Oncohost; Orano Med
Patents, Royalties, Other Intellectual Property - We recently filed a patient "DOPED BEO COMPOUNDS FOR OPTICALLY STIMULATED LUMINESCENCE (OSL) AND THERMOLUMINESCENCE (TL) RADIATION DOSIMETRY" (Inst)
Travel, Accommodations, Expenses - Oncohost
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Black Diamond Therapeutics; Bristol-Myers Squibb; Dompé Farmaceutici; Exact Sciences; Fulcrum Therapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Takeda
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst)
 
Michael Hofman
Consulting or Advisory Role - Janssen; MSD; Novartis (Inst)
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Debiopharm Group (Inst); Novartis
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Aktis Oncology; RayzeBio
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics
 
Lena Unterrainer
Consulting or Advisory Role - Telix Pharmaceuticals
Speakers' Bureau - Astellas Amgen BioPharama; Novartis
Research Funding - Advanced Biochemical Compounds
 
Wolfgang Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; GE Healthcare; Janssen; Lilly
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Ken Herrmann
Leadership - Aktis Oncology; Pharma15
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Ghassan El-Haddad
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Bayer; Canon Medical System; Northstar Medical radioisotopes; TERUMO
Research Funding - Cellectar
Patents, Royalties, Other Intellectual Property - Patent Title: Locking Brakes For Enteral Feeding Tube Retention Member Inventor: Ghassan Elias El-Haddad Patent number: 10,492,999 Issue Date: December 3, 2019 Assignee: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
 
Brian Gonzalez
Stock and Other Ownership Interests - Elly Health
Consulting or Advisory Role - KemPharm; Sure Med Compliance
Patents, Royalties, Other Intellectual Property - FACIT licensing fees (Inst); Trademark (Inst)